Pharma Focus Asia

Bioasis Enters Into Research Collaboration With Janssen

Tuesday, April 12, 2022

Bioasis Technologies Inc., a biopharmaceutical company developing its proprietary xB3TM platform technology for the delivery of therapeutics across the blood-brain barrier (the “BBB”), announced today that it has entered into a research collaboration with Janssen Biotech, Inc., one of the Pharmaceutical Companies of Johnson & Johnson. Under the terms of the agreement, Janssen will have the option to research, develop and commercialize novel products based on Bioasis’ xB3TM platform. The agreement was facilitated by Johnson & Johnson Innovation.

“The unique delivery method of the xB3TM platform has the potential to overcome a significant challenge in the treatment of brain disorders, which is the ability to cross the blood-brain barrier. We are very pleased to have entered into this agreement and excited to be working with Janssen. Our xB3TM BBB drug delivery platform has the potential to significantly advance the treatment of disease, solving a major unmet clinical need and improving the lives of patients,” said Deborah Rathjen, Ph.D., Bioasis’ Executive Chair.

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024